A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
Status:
Completed
Trial end date:
2015-02-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of
ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and
intravenous (IV) and oral administration of 14^C-labeled ertugliflozin in healthy male
participants.